In Taiwan, orphan drugs are registered through the Taiwan Food and Drug Administration (TFDA). The process involves submitting documentation for clinical trial data, safety, and efficacy. Fast-track approval is available for rare diseases, and sponsors can receive incentives like fee reductions and market exclusivity for a certain period.